Enzo Operating Margin from 2010 to 2024
| ENZ Stock | USD 0.98 0.01 1.03% |
Check Enzo Biochem financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enzo Biochem's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.5 M, Interest Expense of 187.2 K or Total Revenue of 63.1 M, as well as many indicators such as Price To Sales Ratio of 1.73, Dividend Yield of 2.0E-4 or PTB Ratio of 0.98. Enzo financial statements analysis is a perfect complement when working with Enzo Biochem Valuation or Volatility modules.
Enzo | Operating Margin |
Latest Enzo Biochem's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Enzo Biochem over the last few years. It is Enzo Biochem's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enzo Biochem's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.39) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Enzo Operating Margin Regression Statistics
| Arithmetic Mean | (0.07) | |
| Coefficient Of Variation | (569.88) | |
| Mean Deviation | 0.27 | |
| Median | (0.12) | |
| Standard Deviation | 0.40 | |
| Sample Variance | 0.16 | |
| Range | 1.759 | |
| R-Value | (0.24) | |
| Mean Square Error | 0.16 | |
| R-Squared | 0.06 | |
| Significance | 0.39 | |
| Slope | (0.02) | |
| Total Sum of Squares | 2.24 |
Enzo Operating Margin History
About Enzo Biochem Financial Statements
Enzo Biochem investors use historical fundamental indicators, such as Enzo Biochem's Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Enzo Biochem. Please read more on our technical analysis and fundamental analysis pages.
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company was founded in 1976 and is headquartered in Farmingdale, New York. Enzo Biochem operates under Diagnostics Research classification in the United States and is traded on New York Stock Exchange. It employs 465 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Enzo Stock Analysis
When running Enzo Biochem's price analysis, check to measure Enzo Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzo Biochem is operating at the current time. Most of Enzo Biochem's value examination focuses on studying past and present price action to predict the probability of Enzo Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzo Biochem's price. Additionally, you may evaluate how the addition of Enzo Biochem to your portfolios can decrease your overall portfolio volatility.